The anti-CD20 monoclonal antibody rituximab (RTX) has been used as a therapeutic option in refractory cases with good results, mainly in patients with SCLE and severe extracutaneous forms of SLE.
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We aim to demonstrate a case of SCLE, refractory to conventional therapy, that was successfully treated with RTX and to review the literature of SCLE cases treated with RTX.
A 31-year-old female, brown-skinned, hypertensive and smoker, has been attending our outpatient clinic since 2002 due to SLE. She presents SCLE, photosensitivity, lymphopenia (456/ml), antinuclear antibodies (ANA) 1/640 with a homogenous pattern, and other immunological alterations (anti-Sm, anti-RNP, anti-Ro).
No signs of renal, neurological or pulmonary impairment have been detected.
Physical examination revealed violaceous, erythematous, annular, exulcerated, and scaly plaques, mainly on sun-exposed areas, and labial mucous damage with exulcerated plaques (Figure 1 FIgure 1: Sun-exposed areas with erythematous, annular, exulcerated, and scaly plaques before treatment with rituximab (RTX)
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The patient had previously been treated with azathioprine (150mg/day), hydroxychloroquine (400mg/day), thalidomide (100mg/day), dapsone (100mg/day), prednisone (0.5 to 1mg/kg/ day), and monthly pulse therapy with methylprednisolone (21 cycles) without complete control of the disease.
As an attempt of treatment, RTX was started at a weekly dose of 375mg/m 2 for 4 weeks, followed by maintenance doses every 6 months. Intravenous methylprednisolone (100mg) was also given with each RTX dose. One month after the first dose, the patient showed significant improvement with a complete and continuous control of the disease, reducing her disease activity index (SLEDAI) from 18 to 4.
Hydroxychloroquine, thalidomide, and dapsone doses were maintained and oral prednisone was gradually tapered without flares throughout a 12-month follow-up ( Figure 2 RTX doses varied from 1g twice a week to 375mg/m² a week for 4 weeks. Maintenance doses, when used, varied from 2 months to 1 year. In the case we report here, the dose was similar to that used in the Australian study (weekly doses of 375mg/m² for 4 weeks). However, since the patient's condition improved significantly and there were no flares, maintenance doses were used every 6 months. 4 Similar to most cases reported in the literature, our patient's condition improved one month after the first RTX dose, which enabled the gradual tapering of prednisone, thus reducing the side effects caused by its chronic use. Some studies reported flares after treatment started, but lesions were cleared after maintenance doses.
Although RTX has shown effective results in the treatment of SCLE, it has not been effective for cutaneous lesions of other forms of CLE, such as CCLE. This suggests that RTX is indicated for lupus manifestations involving Th2 cells, such as serositis, vasculitis, nephritis, ACLE and SCLE, which are mediated by B cells (CD20+).
Further studies are needed in order to recognize RTX as a therapeutic option for SCLE, even though independent results indicate that it is effective in the treatment of refractory SCLE. Data regarding dose / frequency of administration, drug tolerability, side effects, and long-term remission are still lacking given the small number of reported cases. q Quinine-induced ototoxicity is manifested by auditory and vestibular dysfunction; however, its exact mechanism is yet not well established. The drug is absorbed by the gastrointestinal tract and most of it is deposited in the tissues, with only a minimal portion excreted. 2 Chloroquine builds up and remains selectively fixed to melanocytes, and high levels of the drug are present in the stria vascularis, retinal pigment, skin, hair follicle and endocrine glands. 1 Ototoxicity is related to the destruction of the stereocilia in varying degrees, reducing the neuron population, altering the support structures, causing atrophy of the stria vascularis and potentially leading to ischemia. 1 Melanin is present in the inner ear in highly vascular areas, thus, blood vessels are usually surrounded by melanocytes.
In this context, it is believed that the buildup of chloroquine is responsible for a vascular injury and degenerative changes in the planum semilunatum and stria vascularis. These abnormalities of the epithelial tissues could result in an alteration of the structure of the endolymph, leading to damage of the cellular receptor. 2 The buildup and long-term retention of antimalarial in melanocytes of the inner ear could explain the late onset of lesions and the relationship with elevated cumulative doses. 
